Human epidermal growth factor receptor 2 (HER-2) is a protooncogene that is strongly expressed in 20-30% of breast tumors and is linked to a poor prognosis, an increased risk of metastasis, and resistance to treatment for breast cancer 24. This evidence concerns the gene ERBB2 and breast carcinoma.